Key result
Sacubitril/valsartan linked to improved quality of life in systemic RV failure, including ~3-point higher cognitive scores.
Why the study?
Short-term improvements in quality of life have been reported with sacubitril/valsartan in adult congenital heart disease patients with systemic right ventricular failure, but medium-term changes remained to be evaluated.
Does sacubitril/valsartan improve self-perceived quality of life in adult congenital heart disease patients with systemic right ventricular failure?
Cohort (n=40)
Open-label
No
Does sacubitril/valsartan improve self-perceived quality of life in adult congenital heart disease patients with systemic right ventricular failure?
Sacubitril/valsartan is associated with persistent medium-term improvements in several quality-of-life domains for ACHD patients with systemic right ventricular failure, highlighting its potential psychosocial and physical benefits.
Answers are grounded in this paper and cite their sources.
May support sacubitril/valsartan for QoL in systemic RV failure; leaves open benefit in ACHD pending randomized trials.
BACKGROUND: Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term QOL changes in sRV failure patients treated with sacubitril/valsartan. METHODS: In this single-centre, prospective cohort study, patients with symptomatic sRV failure completed the Netherlands Organisation for Applied Scientific Research/Academic Hospital Leiden Questionnaire for Adult's Health-Related Quality of Life (TAAQOL) at baseline and after starting treatment with sacubitril/valsartan. The TAAQOL was taken at structured outpatient follow-up moments after 6, 12, 24 and 36 months of treatment. Linear mixed effects models were used to evaluate the medium-term changes in 12 QOL domains. RESULTS: Of 40 sRV failure patients initiated on sacubitril/valsartan, 35 completed the titration phase, and 31 filled in a total of 98 TAAQOL questionnaires (response rate 77.5%). Significant improvements in gross motoric functioning (p=0.008), cognitive function (p=0.002), sleep (p=0.041), social functioning (p<0.001) and daily activities (p=0.001) were observed during follow-up. No significant changes were observed in fine motoric functioning, pain, sexuality, vitality, positive, depressive or aggressive emotions. Of interest, periods with restrictions relating to the COVID-19 pandemic did not significantly influence changes over time in any of the 12 QOL domains. CONCLUSIONS: Sacubitril/valsartan treatment was associated with persistent medium-term QOL improvements in gross motoric functioning, cognitive function, sleep, social functioning and daily activities domains in sRV failure patients. Self-perceived QOL of sRV failure patients may be amenable to improvement with sacubitril/valsartan.
No takes yet. Share an insight, caveat, or question.
Neijenhuis et al. (2025) conducted a cohort in Systemic right ventricle (sRV) failure (n=40). Sacubitril/valsartan was evaluated on Change in cognitive function quality of life domain (TAAQOL) (Coefficient 2.69, 95% CI 1.10-4.29, p=0.002). Sacubitril/valsartan was associated with significant medium-term quality of life improvements in sRV failure patients, including a significant increase in the cognitive function domain.
Synapse has enriched 10 related papers. Consider them for comparative context: